Valuation: Lantheus Holdings, Inc.

Capitalization 6.11B 5.25B 4.81B 4.56B 8.4B 589B 8.55B 57.53B 22.3B 279B 22.95B 22.46B 971B P/E ratio 2026 *
22.6x
P/E ratio 2027 * 17.7x
Enterprise value 5.86B 5.04B 4.61B 4.38B 8.06B 565B 8.2B 55.18B 21.39B 267B 22.01B 21.54B 932B EV / Sales 2026 *
4x
EV / Sales 2027 * 3.36x
Free-Float
88.16%
Yield 2026 *
-
Yield 2027 * -
1 day-0.84%
1 week-1.49%
Current month+9.51%
1 month+10.36%
3 months+26.84%
6 months+73.21%
Current year+39.25%
1 week 92.18
Extreme 92.175
98.27
1 month 80
Extreme 80
98.27
Current year 63.37
Extreme 63.37
98.27
1 year 47.25
Extreme 47.25
98.27
3 years 47.25
Extreme 47.25
126.89
5 years 19.3
Extreme 19.301
126.89
10 years 1.92
Extreme 1.92
126.89
Manager TitleAgeSince
Chief Executive Officer 66 31/12/2025
Director of Finance/CFO 60 20/09/2018
Chief Tech/Sci/R&D Officer 64 31/07/2025
Director TitleAgeSince
Director/Board Member 80 30/04/2012
Chairman 66 29/02/2024
Director/Board Member 61 31/12/2016
Change 5d. change 1-year change 3-years change Capi.($)
-0.67%-1.49%+18.43%-3.49% 6.11B
+0.08%-2.44%+134.47%+219.61% 12.59B
+0.42%+0.14%-39.94%-27.63% 9.82B
-3.68%+3.88%-10.76%-12.33% 5.91B
-1.26%-3.53%+84.99%+82.05% 4.57B
+0.03%+5.67%-24.99%-30.63% 4.34B
+4.12%-5.65% - - 4.11B
-0.27%-1.79%-14.82%-42.82% 2.82B
+2.24%+4.54%+139.98%-61.04% 2.69B
-1.81%-10.34%-1.81%+24.82% 1.52B
Average -0.11%-1.34%+31.73%+16.50% 5.45B
Weighted average by Cap. -0.11%-0.48%+38.94%+47.52%

Financials

2026 *2027 *
Net sales 1.46B 1.26B 1.15B 1.09B 2.01B 141B 2.05B 13.78B 5.34B 66.75B 5.5B 5.38B 233B 1.66B 1.42B 1.3B 1.24B 2.28B 160B 2.32B 15.59B 6.04B 75.51B 6.22B 6.09B 263B
Net income 266M 229M 209M 199M 366M 25.67B 372M 2.51B 972M 12.14B 1B 979M 42.33B 343M 295M 270M 256M 472M 33.07B 480M 3.23B 1.25B 15.65B 1.29B 1.26B 54.54B
Net Debt -250M -214M -196M -186M -343M -24.04B -349M -2.35B -910M -11.38B -937M -917M -39.65B -546M -469M -429M -408M -750M -52.58B -763M -5.14B -1.99B -24.88B -2.05B -2.01B -86.72B
Logo Lantheus Holdings, Inc.
Lantheus Holdings, Inc. is a radiopharmaceutical-focused company, dedicated to helping clinicians find, fight, and follow disease to deliver better patient outcomes. The Company's product categories include Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships and Others. The Company's Radiopharmaceutical Oncology products help healthcare professionals (HCPs) find, fight and follow cancer. The Company's Precision Diagnostic products assist HCPs to find and follow diseases. Its Strategic Partnerships include biomarkers and digital solutions in support of its partners’ therapeutic development, out-licensing agreements for non-core assets and optimization of its assets geographically. The Company's commercial products are used by cardiologists, internal medicine physicians, neurologists, nuclear medicine physicians, oncologists, radiologists, sonographers, technologists, and urologists working in a variety of clinical settings.
Employees
1,193
Date Price Change Volume
18/05/26 92.84 $ -1.14% 930,496
15/05/26 93.91 $ -2.86% 926,932
14/05/26 96.67 $ +0.22% 843,451
13/05/26 96.46 $ +0.24% 1,008,602
12/05/26 96.23 $ +2.30% 1,230,212
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
93.91USD
Average target price
104.08USD
Spread / Average Target
+10.83%

Quarterly revenue - Rate of surprise